Asian Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Formulation and Charaterization of Antifungal Drug Microemulsion Hydrogel for Topical Drug Delivery


Affiliations
1 Assistant Professor, Department of Pharmaceutical, SIRTS Pharmacy, Bhopal (M.P.), India
     

   Subscribe/Renew Journal


Clotrimazole is a broad-spectrum antimycotic drug, Candida albicans as well as other fungal infections are typically treated with this drug. “Clinical clotrimazole seems to be a topical therapy treating tineapedis (athlete's foot), vulvovaginal candidiasis, and oropharyngeal candidiasis.” That is a synthetic azole antimycotic. It inhibits fungal growth by decreasing the production of ergosterol. Clotrimazole has become a medication of interest for a variety of illnesses, including sickle cell anaemia, malaria, and some cancers, in addition to its antimycotic properties. It's been mixed with other molecules as well, to create clotrimazole compounds with enhanced pharmacological effectiveness, including such metals. Numerous novel pharmaceutical formulations enabling variable releases are also being developed. Clotrimazole is a well-tolerated, little-adverse drug, however certain immune compromised individuals are developing treatment resistance. Clotrimazole's pharmaceutical chemistry, use, and pharmacology are discussed in this study.

Keywords

Antifungal Property, Microemulsion Hydrogel
Subscription Login to verify subscription
User
Notifications
Font Size


  • Carbone. C., Teixeira. M. D. C., Sousa. M. D. C., Martins-Gomes. C., Silva. A. M., Souto. E. M. B., and Musumeci. T., “Clotrimazole-loaded Mediterranean essential oils NLC: a synergic treatment of Candida skin infections. Pharmaceutics”, 2019, 11(5), 231.

  • Blokhina. S., Sharapova. A., Ol’khovich. M., and Perlovich. G. “Experimental solubility of clotrimazole and some thermodynamic aspects of dissolution in different solvents, 2019,682.

  • Mehta D. P., Rathod H. J., and Shah D.P. “Design, development and characterization of microemulsion based hydrogel of clotrimazole for topical delivery system”,2019,1-10.

  • Carbone C., Fuochi V., Zielińska A., Musumeci L., Souto E.B., Bonaccorso A., Puglia C., Petronio Petronio, P.M. Furneri, “Dual-drugs delivery in Solid Lipid Nanoparticles for the treatment of Candida albicans mycosis, Colloids and Surfaces B: Biointerfaces”, 2019,10,70.

  • Victor Midlej, Felipe Rubim, Wilmer Villarreal, Érica S. Martins-Duarte, Maribel Navarro, Wanderley de Souza, Marlene Benchimol, Zinc-clotrimazole complexes are effective against Trichomonas vaginalis, Parasitology, 2019, 1-11.

  • Vainstein, Mário Lettieri Teixeira, Ricardo José Alves, Alexandre Meneghello Fuentefria, “Chloroacetamide derivatives as a promising topical treatment for fungal skin infections, Mycologia”, 2019, 1-12.

  • Chaiyakarn Pornpitchanarong, Kanokwan Singpanna, Theerasak Rojanarata, Praneet Opanasopit, Tanasait Ngawhirunpat, Prasopchai Patrojanasophon, Catechol-Bearing Hyaluronic Acid Coated Polyvinyl Pyrrolidone/ Hydroxyl Propyl-β- Cyclodextrin/Clotrimazole Nanofibers for Oral Candidiasis Treatment, Key Engineering Materials, 2019, 163-168.

  • Ali A., Muhammad, I. N., Hasan, S. F., and Mushtaque, M. “Development and Pharmaceutical Evaluation of Clotrimazole Loaded Topical Hydrogel Formulation”, 2018, 675-81.

  • Atefeh Zare, Zeinab Moshfeghy, Mohammad M. Zarshenas, Bahia Namavar jahromi, Marzieh Akbarzadeh, Mehrab Sayadi, Quercus Brantii Lindl. “Vaginal Cream versus Placebo on Bacterial Vaginosis: a Randomized Clinical Trial, Journal of Herbal Medicine”, 2018, 11, 003.

  • Amanpreet Kaur, Kiran Jyoti, Ashish Baldi, Upendra Kumar Jain, Ramesh Chandra, Jitender Madan, “Self-assembled nanomicelles of amphiphilic clotrimazole glycyl-glycine analogue augmented drug delivery, apoptosis and restrained melanoma tumour progression, Materials Science and Engineering”, 2018.03.030, 89, 75-86.

  • Daniel Escorsim Machado, Jamila Alessandra Perini, Erika Menezes de Mendonça, Jessica Ristow Branco, Karina Cristina Rodrigues-Baptista, Jessica Alessandra-Perini, Jair Machado Espíndola-Netto, Thiago Alves dos Santos, Wagner Santos Coelho, Luiz Eurico Nasciutti, Mauro Sola-Penna, Patricia Zancan, Clotrimazole is effective for the regression of endometriotic implants in a Wistar rat experimental model of endometriosis, Molecular and Cellular Endocrinology, 10.1016/j.mce.2018.04.005, 476, 17-26.

  • Blanca Regina de la Paz Cota, Pedro Pablo Cepero Vega, Juan José Matus Navarrete, Gerardo Efrain Aguado Mulgado, José Juan Narváez Huerta, Enrique Lamadrid Bautista, Epifanio Fiscal Chauteco, “Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis, American Journal of Otolaryngology”, 2018, 017, 307-312.

  • Thalita Gagini, Legna Colina-Vegas, Wilmer Villarreal, Luana Pereira Borba- Santos, Caroline de Souza Pereira, Alzir Azevedo Batista, Marcos Kneip Fleury, Wanderley de Souza, Sonia Rozental, Luiz Antônio S. Costa, Maribel Navarro, “Metal–azole fungistatic drug complexes as anti- Sporothrix spp. agents, New Journal of Chemistry”, 2018, 13641-13650.

  • Mafalda Cavalheiro, Catarina Costa, Ana Silva-Dias, Isabel M. Miranda, Can Wang, Pedro Pais, Sandra N. Pinto, Dalila Mil-Homens, Michiyo Sato- Okamoto, Azusa Takahashi-Nakaguchi, Raquel M. Silva, Nuno P. Mira, Arsénio M. Fialho, Hiroji Chibana, Acácio G. Rodrigues, Geraldine Butler, Miguel C. Teixeira, “A Transcriptomics Approach To Unveiling the Mechanisms of In Vitro Evolution towards Fluconazole Resistance of a Candida glabrata Clinical Isolate, Antimicrobial Agents and chemotherapy”,2018,10.

  • Crowley, P. D., and Gallagher, H. C. “Clotrimazole as a pharmaceutical: past, present and future, Journal of applied microbiology”, 2014 611-617.

  • Valerio, C., Perillo, T., Brescia, L. and Russo, F. “Antifungal Agents in Current Pediatric Practice”, 2013, 278-287.

  • Porsbring, T., Blanck, H., Tjellström, H. and Backhaus, T. “The pharmaceutical clotrimazole affects marine microalgal communities at picomolar concentrations”, 2009.

  • Martins S., Sarmento B., Souto E.B., Ferreira D.C. – “Insulin-loaded alginate microspheres for oral delivery, Effect of polysaccharide reinforcement on physicochemical properties and release profile. - Carbohyd. Polym.”, 69, 725-731, 2007.

  • Hicks, R.G. “What's new in stable radical chemistry? Org Biomol Chem 5”, 2007, 1321-1338.

  • Sobel, J.D.“Vulvovaginal candidosis”, 2007, 1961-1971.

  • Sweetman, S.C., “Martindale: the complete drug reference ed. Sweetman, S.C. p.764 London: Pharmaceutical Press”, 2007.

  • Kalb, R. and Grossman, M. “Contact dermatitis to clotrimazole. Cutis 36, 240-242.Lorand, T. and Kocsis, B. Recent advances in antifungal agents. Mini-Rev Med Chem 7”, 2007, 900-91.

  • White, T.C., Holleman, S., Dy, F., Mirels, L.F. and Stevens, D.A.“Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother”, 2002,1704- 1713.

  • Eliel, E.L., Wilen, S.H. and Mander, L.N. “Stereochemistry of organic compounds eds”, 1994.

  • Hitchcock, C.A., Dickinson, K., Brown, S., Evans, E. and Adams, D. “Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida”, 1990, 475-480.

  • Eaton, D. and Wilson, K. “Reaction of imidazole and hydroquinone with oxymyoglobin”, 1979, 195-203.

  • Eaton, D.R. and Wilkins, R.G. “Reduction by dithionite ion of adducts of metmyoglobin with imidazole, pyridine, and derivatives”, 1978, 908-915.

  • Sawyer, P. R., Brogden, R. N., Pinder, K. M., Speight, T. M., and Avery, G. S. “Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs”, 1975, 424-447.

  • Eaton, D.R. and Wilkins, R.G. (1978) Reduction by dithionite ion of adducts of metmyoglobin with imidazole, pyridine, and derivatives. J Biol Chem 253, 908–9.


Abstract Views: 131

PDF Views: 0




  • Formulation and Charaterization of Antifungal Drug Microemulsion Hydrogel for Topical Drug Delivery

Abstract Views: 131  |  PDF Views: 0

Authors

Vamakshi Thaker
Assistant Professor, Department of Pharmaceutical, SIRTS Pharmacy, Bhopal (M.P.), India
Praveen Tahilani
Assistant Professor, Department of Pharmaceutical, SIRTS Pharmacy, Bhopal (M.P.), India

Abstract


Clotrimazole is a broad-spectrum antimycotic drug, Candida albicans as well as other fungal infections are typically treated with this drug. “Clinical clotrimazole seems to be a topical therapy treating tineapedis (athlete's foot), vulvovaginal candidiasis, and oropharyngeal candidiasis.” That is a synthetic azole antimycotic. It inhibits fungal growth by decreasing the production of ergosterol. Clotrimazole has become a medication of interest for a variety of illnesses, including sickle cell anaemia, malaria, and some cancers, in addition to its antimycotic properties. It's been mixed with other molecules as well, to create clotrimazole compounds with enhanced pharmacological effectiveness, including such metals. Numerous novel pharmaceutical formulations enabling variable releases are also being developed. Clotrimazole is a well-tolerated, little-adverse drug, however certain immune compromised individuals are developing treatment resistance. Clotrimazole's pharmaceutical chemistry, use, and pharmacology are discussed in this study.

Keywords


Antifungal Property, Microemulsion Hydrogel

References